Description
Indication & Scope
DongWeiZhuo® Netanasvir Phosphate Capsules treats adult patients with chronic hepatitis C virus genotypes 1, 2, 3 and 6 infection who are treatment-naive or treated with interferon before, with or without compensated liver cirrhosis, and it needs to be used in combination with Encofosbuvir.
- Mechanism: It is a broad-spectrum HCV NS5A inhibitor, which binds to NS5A protein to inhibit HCV viral RNA replication and virion assembly, and block the immune escape of the virus.
- Drug class: Direct-acting antiviral drug, HCV NS5A inhibitor, oral antiviral prescription medicine.
- Clinical use: It is a core component of the oral interferon-free direct antiviral regimen for radical treatment of chronic hepatitis C infection.
| Generic Name | Netanasvir Phosphate Capsules |
| Brand Name | DongWeiZhuo |
| Ingredient | Netanasvir Phosphate Capsules |
| Dosage Form | Capsules |
| Package | 0.1g*7 capsules*4 blisters/box |
| Conditions Treated | Chronic hepatitis C virus genotypes 1, 2, 3 and 6 infection, accompanied or not accompanied by compensated liver cirrhosis |
| Taboos | Patients with hypersensitivity to netanasvir phosphate; patients using strong CYP3A4 inducer drugs at the same time; patients with decompensated liver cirrhosis |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 25°C±5°C, seal the container to avoid light |
| Manufacturer | YangGuangChangJiang Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250007 |
| Approval Date | Mar 18, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Fixed daily dose, taken together with Encofosbuvir tablets once a day.
Time: Take medicine once a day continuously for 12 weeks for patients without liver cirrhosis.
Instructions for use: Take orally with food to improve drug absorption. Do not miss any dose, and complete the whole course of treatment to avoid viral drug resistance.
Interaction: Strong CYP3A4 inducers will reduce the efficacy of netanasvir, and moderate CYP3A4 inhibitors will increase its blood concentration. Combined use with rifampicin and carbamazepine is prohibited.
Side effects: Headache, fatigue, nausea, insomnia, pruritus and mild elevation of liver transaminase.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the clinical application of Netanasvir Phosphate Capsules?
It treats chronic hepatitis C genotypes 1, 2, 3, and 6 in combination with Encofosbuvir.
What is Netanasvir Phosphate Capsules' mechanism of antiviral action?
It inhibits HCV NS5A protein function to block viral RNA replication and virion assembly.
What drugs should be avoided during medication of Netanasvir Phosphate Capsules?
Strong CYP3A4 inducers such as rifampicin and carbamazepine are prohibited.
What are the common adverse reactions of Netanasvir Phosphate Capsules?
Headache, fatigue, nausea, insomnia, pruritus, and mild liver enzyme elevation are typical symptoms.
DongWeiZhuo® | Netanasvir Phosphate Capsules | HCV | DengYueRX
INN: Netanasvir Phosphate Capsules
Indications: Chronic hepatitis C virus genotypes 1, 2, 3 and 6 infection
Dosage Form: Capsules
Strength: 0.1g/capsule
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
